Zou Weiping
Tulane University Health Sciences Center, Section of Hematology and Medical Oncology, 1430 Tulane Avenue, New Orleans, Louisiana 70112-2699, USA.
Nat Rev Cancer. 2005 Apr;5(4):263-74. doi: 10.1038/nrc1586.
It is well known that many tumours are potentially immunogenic, as corroborated by the presence of tumour-specific immune responses in vivo. Nonetheless, spontaneous clearance of established tumours by endogenous immune mechanisms is rare. Therefore, the focus of most cancer immunotherapies is to supplement essential immunogenic elements to boost tumour-specific immunity. Why then has tumour immunotherapy resulted in a generally poor clinical efficiency? The reason might lie in the increasingly documented fact that tumours develop diverse strategies that escape tumour-specific immunity.
众所周知,许多肿瘤具有潜在的免疫原性,体内存在肿瘤特异性免疫反应就证实了这一点。然而,内源性免疫机制自发清除已形成肿瘤的情况很少见。因此,大多数癌症免疫疗法的重点是补充关键的免疫原性成分,以增强肿瘤特异性免疫。那么,为什么肿瘤免疫疗法的临床疗效普遍较差呢?原因可能在于越来越多的文献记载表明,肿瘤会形成多种逃避肿瘤特异性免疫的策略。